Registrars: | Equiniti |
Brands: | Lucozade, Horlicks, Ribena, Paxil, Seroxat |
CEO: | Emma Walmsley |
CFO: | Iain Mackay |
Independent Non-Executive Director: | Urs Rohner |
Independent Non-Executive Director: | Elizabeth (Liz) McKee Anderson |
Independent Non-Executive Director: | Anne Beal |
Independent Non-Executive Director: | Jesse Goodman |
Independent Non-Executive Director: | Harry (Hal) C. Dietz |
Independent Non-Executive Director: | Vishal Sikka |
Non-Executive Chairman: | Jonathan Symonds |
Senior Independent Non-Executive Director: | Charles Bancroft |
Non-Executive Dir: | Hal Barron |
Address: | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS |
Phone: | +44 (0)20 8047 5000 |
Website: | http://www.gsk.com |
Sector: | Pharma and Biotech(LSE) |
Index: | techMARK, FTSE 100, FTSE 350, FTSE All-Share |
Overseas Listings: | BATSLON:GSKL, NYSE:GSK |
ISIN: | GB00BN7SWP63 |
Currency | UK Pounds |
Share Price | 1,433.80p |
Change Today | 20.80p |
% Change | 1.47 % |
52 Week High | 2,263.00 |
52 Week Low | 1,296.00 |
Volume | 1,684,051 |
Shares Issued | 4,094.22m |
Market Cap | £58,703m |
RiskGrade | 129 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 2 |
Buy | 6 |
Neutral | 15 |
Sell | 1 |
Strong Sell | 1 |
Total | 25 |
Latest | Previous | |
---|---|---|
Q3 | Q2 | |
Ex-Div | 17-Nov-22 | 18-Aug-22 |
Paid | 12-Jan-23 | 06-Oct-22 |
Amount | 13.75p | 16.25p |
Time | Volume / Share Price |
14:08 | 296 @ 1,433.80p |
14:08 | 481 @ 1,433.80p |
14:08 | 44 @ 1,434.20p |
14:08 | 141 @ 1,434.20p |
14:08 | 53 @ 1,434.20p |
You are here: research